| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/DDG.13012_G |
| P698 | PubMed publication ID | 27373242 |
| P2093 | author name string | Stephan Grabbe | |
| Peter Mohr | |||
| Berenice M Lang | |||
| Sophia M Wilden | |||
| P2860 | cites work | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 |
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| Combined vemurafenib and cobimetinib in BRAF-mutated melanoma | Q27853076 | ||
| Improved overall survival in melanoma with combined dabrafenib and trametinib | Q27853091 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| PD-1 and its ligands in tolerance and immunity | Q28131650 | ||
| Hepatotoxicity with combination of vemurafenib and ipilimumab | Q28288255 | ||
| Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma | Q28543960 | ||
| Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
| Pembrolizumab versus Ipilimumab in Advanced Melanoma | Q29618134 | ||
| Immunologic correlates of the abscopal effect in a patient with melanoma | Q29620334 | ||
| Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab | Q29620596 | ||
| Nivolumab and ipilimumab versus ipilimumab in untreated melanoma | Q29620657 | ||
| Nivolumab in previously untreated melanoma without BRAF mutation | Q29620688 | ||
| Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial | Q29620814 | ||
| Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort | Q30828178 | ||
| Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma | Q30890582 | ||
| Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. | Q33421351 | ||
| Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival | Q34048270 | ||
| Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor | Q34484174 | ||
| Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 | Q34567635 | ||
| Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial | Q34670965 | ||
| Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab | Q35289145 | ||
| Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. | Q36256712 | ||
| Genomic correlates of response to CTLA-4 blockade in metastatic melanoma | Q37319470 | ||
| Ipilimumab and radiation therapy for melanoma brain metastases | Q37481186 | ||
| Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy | Q37809156 | ||
| Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. | Q38004628 | ||
| Immunotherapy and radiation therapy: considerations for successfully combining radiation into the paradigm of immuno-oncology drug development | Q38227203 | ||
| Clinical blockade of PD1 and LAG3--potential mechanisms of action | Q38298241 | ||
| Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial | Q38404655 | ||
| Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential | Q38414485 | ||
| Immunologic correlates in the course of treatment with immunomodulating antibodies | Q38475103 | ||
| Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma. | Q38584434 | ||
| Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. | Q38657957 | ||
| Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis. | Q39004691 | ||
| Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma | Q46110144 | ||
| Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study | Q46570875 | ||
| Cutting Edge: CTLA-4 on Effector T Cells Inhibits In Trans | Q56888747 | ||
| Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma | Q57781473 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 685-695 | |
| P577 | publication date | 2016-07-01 | |
| P1433 | published in | JDDG | Q15753048 |
| P1476 | title | Immune checkpoint inhibitors: a milestone in the treatment of melanoma | |
| P478 | volume | 14 |
| Q38860973 | Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma |
| Q93007229 | Modulating Tumor Cell Functions by Tunable Nanopatterned Ligand Presentation |
| Q47290990 | Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices |
| Q64082865 | RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy |
| Q52758918 | Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients. |
Search more.